Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis/Penn To Research Chimeric Antigen Receptor Immunotherapies

This article was originally published in The Pink Sheet Daily

Executive Summary

The Anglo/Swiss pharma will work with University of Pennsylvania researchers to discover, develop and commercialize CAR immunotherapy drugs for cancer, while also establishing a joint R&D facility at the Philadelphia campus.

Advertisement

Related Content

Novartis’s Luxturna Deal Expands Gene Therapy Ambitions
CAR T-cell Therapy Shines In ALL; Safety Fix Highlighted At ASH
Servier Links Up With Celladon For Potential Diabetes Drugs
Deals Of The Week: Novartis Places Bid To Dominate In Cancer
As Provenge Sales Dip, Dendreon Hopes Restructuring Is The Answer

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS074601

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel